|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the potential clinical implications of MDM2 amplification in renal cell carcinoma are discussed.
|
31732813 |
2019 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we propose that concurrent activation of p53 and HIF1α may effectively result in cancer-cell apoptosis, and that combined MDM2 antagonists and mTOR inhibitors may be useful in RCC therapy.
|
26937175 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that TGase 2 competes with human double minute 2 homolog (HDM2) for binding to p53; promotes autophagy-dependent p53 degradation in renal cell carcinoma (RCC) cell lines under starvation; and binds to p53 and p62 simultaneously without ubiquitin-dependent recognition of p62.
|
27031960 |
2016 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The T309G MDM2 polymorphism is an independent prognostic factor for patients with RCC, with the TT genotype being associated with worse prognosis.
|
25415135 |
2015 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we provide mechanistic evidence that HIF-2α can be degraded in cytoplasm under hypoxic conditions via the 26S proteasome and that MDM2 is the E3 ligase which induces the hypoxic degradation of HIF-2α in PI-3K-dependent manner in VHL-deficient RCC cells.
|
25578041 |
2015 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that future investigations of therapeutic strategies for RCC should incorporate MDM2 antagonism as part of strategies aimed at rescuing/augmenting p53 tumour suppressor function.
|
25067787 |
2014 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The evasion of p53 function (possibly through the expression of HDMX) is an essential element in the development of resistance to VEGF-targeted therapy in RCC.
|
23497256 |
2013 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.
|
23019224 |
2012 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of p53 in RCC is strongly linked with MDM2 up-regulation (P < 0.001).
|
21756282 |
2012 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our studies identify a novel protein-protein interaction between MDM2 and NME2, which suggests a mechanism that could explain the link between MDM2 expression and poor patient survival in RCC.
|
21504894 |
2011 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, this is the first study to show that a variant genotype of p53 Arg(72)Pro or MDM2 SNP309 may modify the arsenic-related RCC risk even in a non-obvious arsenic exposure area.
|
21982800 |
2011 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, in renal cell carcinoma (RCC) p53/MDM2 co-expression is associated with reduced survival which is independently linked with metastasis.
|
21034743 |
2010 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this review was to focus attention on 2 such genes, p53 and murine double minute 2 (MDM2), and to provide a comprehensive summary and critical analysis of the literature regarding these genes in RCC.
|
20052733 |
2010 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM-2 antagonists did not induce significant cell death in RCC cell lines, even with induction of p53-dependent pro-apoptotic genes.
|
20953142 |
2010 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed in the TFE3-positive carcinoma an intense immunoreaction for p21 ((wafl/cip1)), cyclin D1, and cyclin D3, without expression for p53, p16, p27(kip1), and mdm2, whereas the immunoexpression profile observed in the classic RCC was similar to that of clear cell, adult-type RCC.
|
19246164 |
2009 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
This study identifies a novel role for the HDM2 oncoprotein in the regulation of angiogenic factors in renal cell carcinoma.
|
18199551 |
2008 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
To investigate the effect of the MDM2 SNP309 polymorphism on MDM2 expression, immunohistochemistry was done in genotyped RCC tissues.
|
17634539 |
2007 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A significant increase in the GG genotype of the MDM2 SNP309 was observed in RCC patients compared with healthy controls (odds ratio, 1.80; 95% confidence interval, 1.14-2.84).
|
17634539 |
2007 |
|
Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, it is important that we gain a clearer understanding of the regulation of p53 and the role of MDM2 in renal cell cancer.
|
16061625 |
2005 |
|
Renal Cell Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our results demonstrate that RCCs from patients living in the radio-contaminated areas showed aberrant hypermethylation of p14(ARF) and p16(INK4A) genes, associated with increased p38MAPK, p14(ARF), mdm2, cyclinD1 and Ki67 protein expression levels.
|
15232742 |
2004 |
|
Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional and expression analysis of Mdm2, MdmX, and Arf showed lack of involvement of these p53 regulators in the observed defect of p53 function in RCC.
|
15026329 |
2004 |
|
Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
p53 mutations and MDM-2 amplification in renal cell cancers.
|
7824511 |
1994 |